Triple-negative breast cancer is a fast-moving form of breast cancer that’s more common in younger women and harder to treat using standard therapies. But with early detection, the right treatment ...

Trodelvy plus Keytruda may maintain QOL and delay physical decline in PD-L1-positive mTNBC patients. The combination therapy showed improved progression-free survival and reduced symptom burden ...

Personalis ((PSNL)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...

Triple negative breast cancer (TNBC) is one of the most aggressive and hardest forms of breast cancer to treat, but a new study led by Weill Cornell Medicine suggests a surprising way to stop it from ...

Oct 19 (Reuters) - Gilead Sciences' (GILD.O), opens new tab Trodelvy lowered the risk of disease progression in an aggressive type of breast cancer by 38% when used as an initial treatment, according ...

A new study found that the degree of immune enrichment predicted radiosensitivity. The radiosensitivity index (RSI), a validated genomic marker, was higher in pretreatment immune-enriched ...

Breast cancer accounts for nearly one-third of all cancers in women, and one of the most aggressive subtypes is triple-negative breast cancer (TNBC). Researchers at Nanjing University and Nantong ...